Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL A randomized phase III study of ramucirumab RAM plus docetaxel DOC vs DOC for second line treatment of stage IV non small cell lung cancer NSCLC